A method of predicting RIP2 inhibitor efficacy in treating a subject with an inflammatory disorder includes obtaining a bodily sample from the subject, determining in the bodily sample the expression level(s) of at least one gene selected from the group consisting of cd40, Clec4E, clec5a, CxCL10, gpr84, Icam1, Irgl, Marcks11, pde4b, Ptges, Rasgrp1, and slc2a6,comparing the expression levels of the at least one gene with the corresponding control value(s), and characterizing the subject as being responsive to RIP2 inhibitor treatment if the expression levels of the at least one gene is increased compared to the corresponding control value(s).
